A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

King Faisal Specialist Hospital & Research Center46 enrolled

Overview

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Study Type

OBSERVATIONAL

Enrollment

Conditions

Metastatic Colorectal Cancer

Interventions

Capecitabine (Xeloda), Oxaliplatin, Irinotecan, BevacizumabDRUG

Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Eligibility

Sex: ALLMin age: 14 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with diagnosed Metastatic Colorectal Cancer Exclusion Criteria: * Patients with diagnosis other than Metastatic Colorectal Cancer

Locations (1)

Kfsh & Rc

Riyadh, Saudi Arabia

RECRUITING

Central Contacts

Shouki Bazarbashi, M.D.

CONTACT

+966-1-4423949

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.